MarketPeel
Insider Trading Intelligence
Pricing
…
DL

Deerfield Mgmt Iv, L.p.

NUVL
DIRECTOR · NUVALENT, INC. · CIK 0001713467
FILING MIX · LIFETIME49%/51%
BUYS
41
SELLS
43
TOTAL VALUE
$414.20M
COMPANIES
11
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
41,829,448
AVG SELL PX
$50.92
TRADE KIND
SHOWING 84 / 84
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
46 backtested trades · 8 horizons · 29 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Deerfield Mgmt Iv, L.p., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d46+78.26%-5.54%-1.10%-4.44%-5.19%-3.22
14d46+65.22%-2.36%-0.85%-1.51%-5.51%-0.55
30d46+73.91%-8.07%-0.81%-7.26%-7.21%-2.73
60d46+47.83%-3.81%+1.49%-5.31%-10.04%-1.50
90d46+45.65%-3.90%+2.05%-3.02%+0.34%-0.64
180d46(4 pending)+69.05%-4.91%+5.16%-10.01%-16.92%-1.85
1y46(8 pending)+50.00%-8.64%+9.48%-18.12%-19.47%-1.75
2y46(17 pending)+27.59%-0.44%+25.26%-25.70%-44.44%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NUVL · 8,299,225 shares · as of Nov 24, 2025
03,252,9976,505,9949,758,99113,011,9882022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 41 buys / 43 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,000,000$5.00$10.00M6,207,982Feb 27, 2026Mar 2, 2026 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,084,010$5.00$5.42M10,622,928Feb 27, 2026Mar 2, 2026 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
831,978$5.00$4.16M8,153,107Feb 27, 2026Mar 2, 2026 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,084,012$5.00$5.42M10,622,957Feb 27, 2026Mar 2, 2026 ↗View →
NUVL
NUVALENT, INC.
SALE
371,287$95.45$35.44M8,299,225Nov 24, 2025Nov 24, 2025 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,599,932$3.20$8.32M7,321,129Jul 31, 2025Aug 4, 2025 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
3,387,529$3.20$10.84M9,538,918Jul 31, 2025Aug 4, 2025 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
3,387,539$3.20$10.84M9,538,945Jul 31, 2025Aug 4, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
370,074$18.46$6.83M4,887,254Jun 27, 2025Jul 1, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
370,075$18.46$6.83M4,887,254Jun 27, 2025Jul 1, 2025 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
9,553$17.77$169.8K5,257,328Nov 12, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
9,554$17.77$169.8K5,257,329Nov 12, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
7,853$17.16$134.8K5,266,883Nov 12, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
7,854$17.16$134.8K5,266,881Nov 12, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
223,632$18.15$4.06M5,274,735Nov 11, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
40,596$17.45$708.4K5,498,367Nov 11, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
223,632$18.15$4.06M5,274,736Nov 11, 2024Nov 13, 2024 ↗View →
SPRY
ARS PHARMACEUTICALS, INC.
SALE
40,596$17.45$708.4K5,498,368Nov 11, 2024Nov 13, 2024 ↗View →
NUVL
NUVALENT, INC.
SALE
1,000,000$97.75$97.75M8,670,512Oct 22, 2024Oct 24, 2024 ↗View →
AHCO
ADAPTHEALTH CORP.
SALE
114,906$10.70$1.23M11,528,863Mar 12, 2024Mar 12, 2024 ↗View →
AHCO
ADAPTHEALTH CORP.
SALE
94,567$10.92$1.03M11,731,809Mar 11, 2024Mar 12, 2024 ↗View →
AHCO
ADAPTHEALTH CORP.
SALE
88,040$11.13$979.9K11,643,769Mar 11, 2024Mar 12, 2024 ↗View →
AHCO
ADAPTHEALTH CORP.
SALE
4,495$11.03$49.6K11,826,376Mar 8, 2024Mar 12, 2024 ↗View →
AHCO
ADAPTHEALTH CORP.
SALE
47,992$10.92$524.1K11,830,871Mar 8, 2024Mar 12, 2024 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,430,206$8.74$12.50M6,151,406Feb 16, 2024Feb 16, 2024 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,430,205$8.74$12.50M4,207,982Feb 16, 2024Feb 16, 2024 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,430,206$8.74$12.50M6,151,389Feb 16, 2024Feb 16, 2024 ↗View →
NUVL
NUVALENT, INC.
PURCHASE
650,000$33.50$21.77M650,000Nov 3, 2022Nov 7, 2022 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,777,777$3.15$8.75M4,721,197Sep 16, 2022Sep 20, 2022 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,777,777$3.15$8.75M2,777,777Sep 16, 2022Sep 20, 2022 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,777,777$3.15$8.75M4,721,200Sep 16, 2022Sep 20, 2022 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,777,777$3.15$8.75M4,721,183Sep 16, 2022Sep 20, 2022 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
6,909$24.47$169.1K1,704,244Jun 6, 2022Jun 8, 2022 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
11,868$25.29$300.1K1,546,588Jun 6, 2022Jun 8, 2022 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
155$25.08$3.9K1,546,433Jun 6, 2022Jun 8, 2022 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
13,132$25.29$332.1K1,711,324Jun 6, 2022Jun 8, 2022 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
171$25.08$4.3K1,711,153Jun 6, 2022Jun 8, 2022 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
6,243$24.47$152.8K1,540,190Jun 6, 2022Jun 8, 2022 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
625,000——625,000Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
85,113——85,113Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
85,113——0Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
707,960——40Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
40——40Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
50,000$1,000.00$50.00M58,945Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
40——0Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
3,177,543——3,177,543Nov 12, 2021Nov 16, 2021 ↗View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
14,887——85,113Nov 12, 2021Nov 16, 2021 ↗View →
NUVL
NUVALENT, INC.
PURCHASE
897,671——9,670,511Aug 2, 2021Aug 4, 2021 ↗View →
NUVL
NUVALENT, INC.
PURCHASE
8,494,140——8,772,840Aug 2, 2021Aug 4, 2021 ↗View →
NUVL
NUVALENT, INC.
SALE
45,716,568——13,011,988Aug 2, 2021Aug 4, 2021 ↗View →
NUVL
NUVALENT, INC.
PURCHASE
2,417,628——2,417,628Aug 2, 2021Aug 4, 2021 ↗View →
NUVL
NUVALENT, INC.
SALE
4,831,384——0Aug 2, 2021Aug 4, 2021 ↗View →
NUVL
NUVALENT, INC.
SALE
13,011,988——0Aug 2, 2021Aug 4, 2021 ↗View →
NUVL
NUVALENT, INC.
PURCHASE
300,000$17.00$5.10M2,717,628Aug 2, 2021Aug 4, 2021 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
99,325$15.81$1.57M0Jul 9, 2021Jul 13, 2021 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
6,837$15.87$108.5K99,325Jul 7, 2021Jul 7, 2021 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
49,239$16.20$797.4K106,162Jul 6, 2021Jul 7, 2021 ↗View →
MIRM
MIRUM PHARMACEUTICALS, INC.
SALE
10,599$17.01$180.3K155,401Jul 2, 2021Jul 7, 2021 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
228,571$8.75$2.00M1,943,423Jun 30, 2021Jul 2, 2021 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
228,570$8.75$2.00M1,943,420Jun 30, 2021Jul 2, 2021 ↗View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
228,569$8.75$2.00M1,943,406Jun 30, 2021Jul 2, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
SALE
433,551——0Mar 30, 2021Mar 30, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
PURCHASE
625,000$16.00$10.00M3,933,137Mar 30, 2021Mar 30, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
PURCHASE
1,572,960——1,572,960Mar 30, 2021Mar 30, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
SALE
1,572,960——0Mar 30, 2021Mar 30, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
PURCHASE
1,301,626——2,874,586Mar 30, 2021Mar 30, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
SALE
1,301,626——0Mar 30, 2021Mar 30, 2021 ↗View →
EWTX
EDGEWISE THERAPEUTICS, INC.
PURCHASE
433,551——3,308,137Mar 30, 2021Mar 30, 2021 ↗View →
ANNX
ANNEXON, INC.
PURCHASE
458,914——458,914Jul 28, 2020Jul 28, 2020 ↗View →
ANNX
ANNEXON, INC.
SALE
4,043,031——0Jul 28, 2020Jul 28, 2020 ↗View →
ANNX
ANNEXON, INC.
SALE
4,043,032——0Jul 28, 2020Jul 28, 2020 ↗View →
ANNX
ANNEXON, INC.
PURCHASE
350,000$17.00$5.95M808,914Jul 28, 2020Jul 28, 2020 ↗View →
NKTX
NKARTA, INC.
PURCHASE
500,000$18.00$9.00M1,209,936Jul 14, 2020Jul 14, 2020 ↗View →
NKTX
NKARTA, INC.
PURCHASE
709,936——709,936Jul 14, 2020Jul 14, 2020 ↗View →
NKTX
NKARTA, INC.
SALE
2,626,767——0Jul 14, 2020Jul 14, 2020 ↗View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
997,589——997,589Feb 18, 2020Feb 18, 2020 ↗View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
300,000$17.00$5.10M1,297,589Feb 18, 2020Feb 18, 2020 ↗View →
RVMD
REVOLUTION MEDICINES, INC.
SALE
997,589——0Feb 18, 2020Feb 18, 2020 ↗View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
300,000$17.00$5.10M798,795Feb 18, 2020Feb 18, 2020 ↗View →
RVMD
REVOLUTION MEDICINES, INC.
SALE
498,795——0Feb 18, 2020Feb 18, 2020 ↗View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
498,795——498,795Feb 18, 2020Feb 18, 2020 ↗View →
SDGR
SCHRODINGER, INC.
SALE
10,063,061——0Feb 10, 2020Feb 10, 2020 ↗View →
SDGR
SCHRODINGER, INC.
PURCHASE
1,346,167——1,346,167Feb 10, 2020Feb 10, 2020 ↗View →
SDGR
SCHRODINGER, INC.
PURCHASE
250,000$17.00$4.25M250,000Feb 10, 2020Feb 10, 2020 ↗View →
Other insiders · NUVL
Loading peer insiders…
About this filer
CIK 0001713467
ROLE
Director
PRIMARY
NUVL
COMPANIES
11
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001713467DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback